Primary lymphoma of the breast: A case report and review of the literature

Primary breast lymphoma initially diagnosed as invasive ductal carcinoma: A case report

“…According to previous reports, surgery does not improve the prognosis in PBL, 5,14 and surgery is recommended only for diagnostic purposes. Therefore, in our case, surgery was deemed to be unnecessary.…”

“…It is also difficult to distinguish PBL and breast cancer based solely on pathological findings. 5 In a study by Lin et al 6 7 of 41 (17%) hematologic malignant lesions in the breast were misdiagnosed as breast cancer. PBL and breast cancer cells are often morphologically similar; therefore, it may be difficult to distinguish them by hematoxylin-eosin staining alone.…”

“…8 Yoneyama et al reported a similar case, and they highlighted several characteristics, including conspicuous apoptosis, marked nuclear rays due to crushing, and polymorphism in tumor cells, that distinguish breast cancer from PBL. 5 Lin et al also identified several characteristics as findings suspicious of lymphoma, such as lack of in situ lesions, frequent individual karyorrhectic cells, lymphoepithelial lesions, and cellular discohesiveness. 6 On the other hand, on hematoxylin and eosin staining, the shape of the cells, the lack of similar glandular shape, the uniform appearance of the tumor tissue, and the lack of invasiveness into the mammary ducts may have been findings that would have raised suspicion of lymphoma.…”

Primary Lymphomas of the Breast: A Review

“… 9 Systemic type-B symptoms including weight loss, fatigue and fever can also occur in some cases. 10 The causes of PB-DLBCL remain unclear, although post-menopausal oestrogen levels, 11 chronic inflammatory and autoimmune diseases 12 and pregnancy and lactation 13 have been proposed as risk factors.…”

“… 9 The most frequently administered treatment protocol for PB-DLBCL is six cycles of R-CHOP, consisting of rituximab, a monoclonal antibody targeting CD20 which acts to deplete CD20-positive cells and a regimen of four chemotherapy drugs: cyclophosphamide, doxorubicin, vincristine and prednisone. This is often followed by consolidative radiation therapy and/or five doses of intrathecal methotrexate as a prophylactic measure for central nervous system metastasis 9 , 10 , 14 , 15 .…”